Last reviewed · How we verify
tetanus diphtheria toxoids vaccine
The tetanus diphtheria toxoids vaccine stimulates the immune system to produce antibodies against tetanus and diphtheria toxins, providing protective immunity against these bacterial diseases.
The tetanus diphtheria toxoids vaccine stimulates the immune system to produce antibodies against tetanus and diphtheria toxins, providing protective immunity against these bacterial diseases. Used for Prevention of tetanus, Prevention of diphtheria.
At a glance
| Generic name | tetanus diphtheria toxoids vaccine |
|---|---|
| Also known as | Td, Tenivac |
| Sponsor | Biogen |
| Drug class | Toxoid vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxins (toxoids) from Clostridium tetani and Corynebacterium diphtheriae that trigger adaptive immune responses without causing disease. B cells produce specific antibodies that neutralize the actual toxins if exposure occurs, and memory cells provide long-term protection. Booster doses maintain antibody titers above protective thresholds.
Approved indications
- Prevention of tetanus
- Prevention of diphtheria
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia or fatigue
- Headache
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (PHASE1)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Immunosuppression and COVID-19 Boosters (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |